 Patients receive docetaxel intravenously IV over 60 minutes on day 1, prednisone orally PO twice daily BID on days 1-21, and sunitinib malate PO once daily QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. 